The downgrade from Overweight to Neutral by a prominent analyst, along with a significant reduction in the price target, is likely to negatively impact investor sentiment and the short-term stock price of Inari Medical. Such analyst actions often lead to immediate market reactions as investors adjust their expectations based on the new analyst outlook.